Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.
Mol Cancer Ther
; 10(4): 603-14, 2011 Apr.
Article
in En
| MEDLINE
| ID: mdl-21393427
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Recombinant Fusion Proteins
/
Endostatins
/
Antibodies
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Language:
En
Journal:
Mol Cancer Ther
Journal subject:
ANTINEOPLASICOS
Year:
2011
Document type:
Article
Affiliation country:
United States
Country of publication:
United States